BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)
Latest Information Update: 16 Oct 2023
At a glance
- Drugs Talazoparib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms BrUOG 390
- 30 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2022 Status changed from active, no longer recruiting to discontinued.
- 19 Jul 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Sep 2023.